These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 8186356)

  • 1. Strategies for inhibiting the effects of thrombin.
    Harker LA
    Blood Coagul Fibrinolysis; 1994 Jan; 5 Suppl 1():S47-58; discussion S59-64. PubMed ID: 8186356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
    Weitz JI; Hudoba M; Massel D; Maraganore J; Hirsh J
    J Clin Invest; 1990 Aug; 86(2):385-91. PubMed ID: 2384594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin.
    Kelly AB; Maraganore JM; Bourdon P; Hanson SR; Harker LA
    Proc Natl Acad Sci U S A; 1992 Jul; 89(13):6040-4. PubMed ID: 1385867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosteric changes in thrombin's activity produced by peptides corresponding to segments of natural inhibitors and substrates.
    Hortin GL; Trimpe BL
    J Biol Chem; 1991 Apr; 266(11):6866-71. PubMed ID: 1849894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombin activity of a peptide corresponding to residues 54-75 of heparin cofactor II.
    Hortin GL; Tollefsen DM; Benutto BM
    J Biol Chem; 1989 Aug; 264(24):13979-82. PubMed ID: 2760054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin.
    Bates SM; Weitz JI
    Am J Cardiol; 1998 Oct; 82(8B):12P-18P. PubMed ID: 9809887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of antithrombin III-independent thrombin inhibitors and heparin on fibrin accretion onto fibrin-coated polyethylene.
    Rubens FD; Weitz JI; Brash JL; Kinlough-Rathbone RL
    Thromb Haemost; 1993 Feb; 69(2):130-4. PubMed ID: 8456425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of thrombin's clotting activity by synthetic peptide segments of its inhibitors and substrates.
    Hortin GL; Benutto BM
    Biochem Biophys Res Commun; 1990 Jun; 169(2):437-42. PubMed ID: 2357214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Thrombin and its pharmacologic regulation].
    Guillin MC
    Presse Med; 1998 Jun; 27 Suppl 2():22-7. PubMed ID: 9765662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
    Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
    Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct thrombin inhibitors.
    Maffrand JP
    Nouv Rev Fr Hematol (1978); 1992; 34(6):405-19. PubMed ID: 1300540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin.
    Agnelli G; Renga C; Weitz JI; Nenci GG; Hirsh J
    Blood; 1992 Aug; 80(4):960-5. PubMed ID: 1498336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bothrojaracin: a potent two-site-directed thrombin inhibitor.
    Arocas V; Zingali RB; Guillin MC; Bon C; Jandrot-Perrus M
    Biochemistry; 1996 Jul; 35(28):9083-9. PubMed ID: 8703912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP; Bernat A; Gaich C; Herbert M
    Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antithrombin peptide. Characterization of an Arg-Gly-Asp (RGD)- and hirudin carboxyl terminus-containing synthetic peptides.
    Church FC; Phillips JE; Woods JL
    J Biol Chem; 1991 Jun; 266(18):11975-9. PubMed ID: 2050691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis.
    Bossavy JP; Sakariassen KS; Rübsamen K; Thalamas C; Boneu B; Cadroy Y
    Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1348-53. PubMed ID: 10323789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis.
    Biemond BJ; Friederich PW; Levi M; Vlasuk GP; Büller HR; ten Cate JW
    Circulation; 1996 Jan; 93(1):153-60. PubMed ID: 8616922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of endothelial cell-mediated generation of activated protein C by direct and antithrombin-dependent thrombin inhibitors.
    Linder R; Frebelius S; Jansson K; Swedenborg J
    Blood Coagul Fibrinolysis; 2003 Feb; 14(2):139-46. PubMed ID: 12632023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombin inhibition by hirudin: how hirudin inhibits thrombin.
    Fenton JW; Villanueva GB; Ofosu FA; Maraganore JM
    Haemostasis; 1991; 21 Suppl 1():27-31. PubMed ID: 1894193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of hirudin and hirudin PA C-terminal fragments and related analogs as antithrombin agents.
    Krstenansky JL; Owen TJ; Yates MT; Mao SJ
    Thromb Res; 1988 Oct; 52(2):137-41. PubMed ID: 3194888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.